DOCS shares are down approximately 23% in premarket trading on May 14, 2026, following a post-earnings selloff that began after the close on May 13. Primary catalyst: Doximity issued fiscal year 2027 annual revenue guidance of $664M–$676M, falling well short of the Wall Street consensus near $697.4 million.

VEEV shares surged 10.11% to $171.75 in today's trading session from the previous close of $155.97. Primary catalyst: Announcement that VEEV will join the S&P 500 index effective May 7, replacing Coterra Energy ( CTRA ).

Shares of WAY are declining approximately 14.00% on Thursday, April 30, 2026, falling from a prior close of $25.27 to approximately $21.73 — approaching the stock's 52-week low of $21.09 set on April 10 — as Q1 2026 results released April 29 delivered a headline revenue beat that was immediately overshadowed by Q2 2026 sequential revenue guidance of flat to -1% growth, signaling that the momentum trajectory in healthcare payment software is decelerating materially.

CareCloud, Inc. (CCLD) delivers cloud-based software-as-a-service (SaaS) solutions, revenue cycle management (RCM), and electronic health records (EHR) tailored for medical practices. The company's model centers on subscription platforms that handle practice management, patient engagement, and billing, with AI-driven tools adding efficiency.

PHR shares are plunging approximately 26.64% in premarket trading on March 31, 2026, falling from a prior close of $11.41 to $8.37. The primary catalyst is a significant downward revision to fiscal 2027 revenue guidance, cutting the midpoint outlook by roughly $37 million.

An AI-driven comparison of Tempus AI (TEM) and Doximity (DOCS) points to Tempus AI as the more compelling investment opportunity heading into 2026. The analysis highlights TEM’s AI-powered precision medicine platform, which applies advanced analytics and genomic data to transform diagnostics and treatment in oncology and cardiology.

For the Physicians group companies, which include DYNT (Dynatronics), ANGO (AngioDynamics), AMEH (Apollo Medical Holdings), and OPRX (OptimizeRx), the past week has been marked by a significant increase in performance, with a collective gain of +4.41%. However, a deeper look into various indicators and metrics suggests a challenging road ahead for these stocks.

The Diabetes sector has been making headlines recently with a remarkable surge in performance, recording an impressive +11.13% increase over the past week. This surge has sparked considerable interest among investors and analysts alike. In this article, we'll delve into the details of this theme, focusing on the four key tickers that have been at the forefront of this trend: NURO, DRIO, ORGS, and DMAC.

During the previous week, the robot successfully generated a gain of +3.93% while trading TDOC (Teladoc Health Inc.), a medium volatility stock favored for active trading. Despite this commendable performance, recent technical indicators and earnings results indicate potential challenges ahead. In this article, we will analyze the bearish signals triggered by TDOC's Moving Average Convergence Divergence Histogram (MACD) and examine the company's latest earnings report.

Artificial intelligence (AI) has revolutionized various industries, and the financial sector is no exception. In recent years, AI-powered trading bots have gained popularity for their ability to analyze vast amounts of data and execute trades with precision and speed. One such example is the AI Bot Trading system used by TDOC, which has generated impressive gains of 9.1%.

Discover the story behind Doximity's (DOCS) significant decline of -10.93% this month, as we delve into the analysis of the Packaged Software Industry and uncover the prevailing trends that impacted its performance

As a financial analytics and trader, I am thrilled to report on the recent success of an AI trading robot that produced gains of 10.6% for TDOC. This is a clear indication of the power of AI-driven trading, and it highlights the potential for investors to leverage machine learning algorithms to make more informed investment decisions.

As a financial analytics and trader, I am thrilled to report on the recent success of an AI trading robot that produced gains of 10.6% for TDOC. This is a clear indication of the power of AI-driven trading, and it highlights the potential for investors to leverage machine learning algorithms to make more informed investment decisions.

As a technical analyst, let's compare GDC and PINC based on the given information and analyze their earning results:

This AI trading bot, which can be found at Choppy Market Trader, Popular Stocks ($2K per position): Market Neutral Strategy (TA&FA), was a high performer in our robot factory, generating 7.24% for TDOC over the course of the previous week.

According to the information provided, the robot "Choppy Market Trader, Popular Stocks ($4K per position): Market Neutral Strategy (TA&FA)" generated a 7.29% gain for TDOC over the course of the previous week, which is a positive sign.

Veeva Systems is a cloud-computing company that provides software solutions for the life sciences industry. It has been one of the top-performing tech stocks over the past year, with its shares rising by more than 60%. One of the technical indicators that traders use to gauge the momentum of a stock is the Relative Strength Index (RSI). The 10-day RSI Oscillator for VEEV moved out of...

Online healthcare company Teladoc Health’s   shares fell Thursday as several analysts lowered their share-price targets – following lower-than-expected quarterly earnings.

Teladoc reported a loss of -$1.31 a share, steeper than the -40 cents loss expected by analysts.It is also wider than the year-ago quarter’s  -40 cents per share.

Evercore ISI’s Elizabeth Anderson slashed her price target to $185 from $195 and kept her in-line rating.

GoodRx  soared in its debut trading Wednesday on the Nasdaq. The company, a digital prescription price comparison and coupon provider, saw its stock recently traded at $48.45, up +46.81% from its initial public offering price of $33, which in turn was well above the $24 to $28 range set by the underwriters. Inn the six months ended June 30, GoodRx’s net income totaled  $54.7 million, up from $31.2 million a year earlier.Revenue of $256.7 million was higher than $173.2 million a year earlier. Co-founders and CEOs Doug Hirsch and Trevor Bezdek wrote in the prospectus that “so far, we’ve saved Americans an estimated $20 billion on prescriptions and medical services.

Teladoc Health (NYSE: TDOC) is somewhat of a hybrid company, caught between technology and healthcare.Regardless of what the company does, the stock has been in a downward trend for the last seven months.  The decline started last October and it saw the stock drop from over $85 a share to $42.50 in December.